Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

01. April 2026 16:15 ET | Quelle: ARMOUR Residential REIT, Inc.

ARMOUR Residential REIT, Inc. Confirms April 2026 Common Share and Q2 2026 Series C Preferred Share Dividends

VERO BEACH, Florida, April 01, 2026 (GLOBE NEWSWIRE) -- ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) (“ARMOUR” or the “Company”) today confirmed the April 2026 cash dividend for the...
01. April 2026 10:00 ET | Quelle: Origin Modern Health & Wellness

Origin Health Unveils Newly Redesigned Website and Announces Open Registration for 2nd Annual Guardian Initiative Charity Golf Tournament

SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Origin Modern Health & Wellness, a leader in integrative and regenerative healthcare, today announced the official launch of its newly redesigned...
01. April 2026 09:50 ET | Quelle: Faruqi & Faruqi LLP

ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Atara To Contact Him Directly To Discuss Their Options If you purchased or...
01. April 2026 08:00 ET | Quelle: Apollo Global Management, Inc.

Apollo Funds Acquire Gatehouse Living Group from Gatehouse Bank

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Apollo (NYSE: APO) today announced that Apollo-managed funds have acquired Gatehouse Living Group (“GLG” or “the Group”), a vertically integrated UK...
01. April 2026 08:00 ET | Quelle: Cogent Biosciences, Inc.

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)

Bezuclastinib NDA submitted under the FDA’s RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib...
01. April 2026 07:30 ET | Quelle: Medicus Pharma Ltd

Medicus Pharma Ltd Clarifies Positive SkinJect Phase 2 Dataset

PHILADELPHIA, April 01, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development...
01. April 2026 07:00 ET | Quelle: NewGenIVF Group Limited

NewGen Filed 2025 Annual Report on Form 20-F

BANGKOK, April 01, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a technology-driven, diversified growth company, today announced that it has filed its...
01. April 2026 06:01 ET | Quelle: NetBox Labs

NetBox Labs and AHEAD Announce Strategic Partnership to Accelerate Enterprise Infrastructure Modernization, Automation, and AI Readiness

The NetBox Labs platform will be the default foundation for network and infrastructure management for AHEAD enterprise customers.
31. März 2026 20:51 ET | Quelle: Robbins LLP

Did You Lose Money Investing in Atara Biotherapeutics, Inc.? Robbins LLP Encourages Investors with Significant Losses to Contact the Firm About Their Rights Against ATRA

Robbins LLP is Investigating Allegations that Atara Biotherapeutics, Inc. (ATRA) Misled Investors Regarding its Drug Candidate
31. März 2026 19:39 ET | Quelle: Hagens Berman Sobol Shapiro LLP

QURE INVESTOR ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data

Investors who lost money in QURE after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.

Vorherige Seite

Nächste Seite